Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Grows By 200.9%

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 594,279 shares, an increase of 200.9% from the May 14th total of 197,532 shares. Based on an average daily volume of 38,808,369 shares, the days-to-cover ratio is currently 0.0 days. Approximately 7.5% of the company’s shares are short sold.

Insider Buying and Selling at BiomX

In related news, Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $5.00, for a total value of $2,650,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 21.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. bought a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned 5.99% of BiomX as of its most recent SEC filing. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Stock Down 24.2%

PHGE stock opened at $0.54 on Friday. The firm has a market cap of $5.98 million, a price-to-earnings ratio of -0.17 and a beta of 1.18. BiomX has a 12-month low of $0.36 and a 12-month high of $14.71. The company’s fifty day simple moving average is $1.32 and its 200 day simple moving average is $3.18.

BiomX (NYSEAMERICAN:PHGE) last released its earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share (EPS) for the quarter. Research analysts expect that BiomX will post -5.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut shares of BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, BiomX has an average rating of “Hold” and an average price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.